3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
16
Phase 3
7
Phase 1
3
Phase 2/3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
36
Breast Neoplasms
29
Pancreatic Neoplasms
20
Rectal Neoplasms
17
Stomach Neoplasms
16
Neoplasm Metastasis
16
Neoplasms
12
Esophageal Neoplasms
8
Triple Negative Breast Neoplasms
7
Colonic Neoplasms
7
Colorectal Cancer Metastatic
6
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Brain Neoplasms
4
Adenocarcinoma
4
Head and Neck Neoplasms
3
Gastrointestinal Neoplasms
3
Biliary Tract Neoplasms
3
Bile Duct Neoplasms
3
Advanced Solid Tumors
3
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Diabetes Mellitus, Insulin-Dependent, 12
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Interventions
Gemcitabine
4
Oxaliplatin
3
pembrolizumab
2
tivozanib
1
peposertib
1
fludarabine
1
durvalumab
1
devimistat
1
avelumab
1
atezolizumab
1
aldesleukin
1
Temozolomide
1
Specimen Handling
1
Sorafenib
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Radiation
1
Pemetrexed
1
Leucovorin
1
Irinotecan
1
Interleukin-2
1
Fluorouracil
1
Cyclophosphamide
1
Cisplatin
1
Capecitabine
1
Cannabidiol
1
Bortezomib
1
Biopsy
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Gallbladder Neoplasms
×
Capecitabine
×
Clear all
NCT01016639
2011-10-17
CORGI
Lund University Hospital
Phase 1/2
Completed
106 enrolled